Competing for the Future

In the 1990s, while Japanese companies had invaded majority of US and worldwide market in essentially every market segment. Most of managers realized the quality and process are the driving forces for Japanese companies to lead the market share. However, at the same time, Japanese executives and managers had already moved on and eyed the …

Continue reading Competing for the Future

Advertisements

Orange Book Update – Patent Submission Date

It's been quite a while any changes were made in FDA Orange Book. It is welcoming to see FDA is adding/updating NDA holders' patent submission date in Orange Book. At the time of NDA submission, NDA applicants are required to indicate the patents to be listed in Orange Book. Previously, this date is only known …

Continue reading Orange Book Update – Patent Submission Date

Case Study: Strategic Alliances at Millennium Pharmaceuticals

Abstract Millennium Pharmaceuticals, Inc. is one the most successful biotech start-ups in 1990s. Many of Millennium’s high-profile strategic alliances were orchestrated by its visionary CEO Mark Levin and a team of talented entrepreneurs. This article reviews a number of Millennium’s deals, including partnership with large multinational firms and acquisition of small technology companies. A SWOT …

Continue reading Case Study: Strategic Alliances at Millennium Pharmaceuticals

Front End of Innovation

Front End of Innovation (FEI) is defined as those activities come before the formal and structured New Product and Process Development (NPPD) or Stage Gate process. The activities in FEI stage is usually loosely organized without any formal structure and predictable outcome. FEI consists of five inner elements: opportunity identification opportunity analysis idea genesis idea …

Continue reading Front End of Innovation

Case Study: Eli Lilly Drug Development Strategy

Abstract This article analyzes the research and development strategy of Eli Lilly and Company in the mid 1990s. In the 1990s pharmaceutical industry was a highly profitable and fiercely competitive industry. Major pharmaceutical companies poured 15-20% of sales to R&D expenditure in hope to find the next blockbuster drugs. Lilly, a mid-size drug firm vs. …

Continue reading Case Study: Eli Lilly Drug Development Strategy